TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01730014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 148-0287-A-4.2mM-cartridge
Description: In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 148-0287-A-4.2mM-cartridge
Description: In a dose-escalating design, subjects with type 1 diabetes will receive a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium chloride 0.9% w/v
Description: In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.
Study: NCT03488524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMX0035
Description: A combination therapeutic of TUDCA and Sodium Phenylbutyrate
Study: NCT00593320

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Study: NCT02333734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces \~ 90% of the maximum heart rate. The time spent per session is expected to last \~ 25 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical training
Description: Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces \~ 90% of the maximum heart rate. The time spent per session is expected to last \~ 25 minutes.
Study: NCT04248465

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ravulizumab
Description: Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.
Study: NCT01173640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: 2 mg oral dose
Study: NCT02037256

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous hematopoietic stem cell transplantation
Study: NCT01287845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1075553
Description: Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
Study: NCT02847026

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 6 and fIPV at 22 weeks, Rotarix
Description: Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IPV at 6 and fIPV at 22 weeks, RotaTeq
Description: Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV at 6-14-22 weeks of age, Rotarix
Description: Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fIPV at 6-14-22 weeks of age, RotaTeq
Description: Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
Study: NCT00380718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: 500 milligrams per square meter (mg/m2), intravenous (IV) in the first cycle. Acceptable toxicity\* in cycle 1 determines dose increase to 1000 mg/m2 or dose decrease to 375 mg/m2 with unacceptable toxicity every 3 week in subsequent cycles till progression of disease.~\*Toxicity acceptable if none of the following toxicities recorded at any time during Cycle 1: Platelets \<50 x 10\^9/L; absolute neutrophil count \<1.0 x 10\^9/L; Stomatitis/pharyngitis/esophagitis/diarrhea Grade \>2; Skin Grade \>2; Serum bilirubin \>3.0 x upper limit of normal (ULN); alanine aminotransferase/aspartate aminotransferase \>10 x ULN; Other non-hematologic toxicities Grade \>2 (except nausea, vomiting).
Study: NCT00659542

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cyanoacrylate glue
Description: 1 ml glue
Study: NCT03009383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A bedside portable endoscopy
Study: NCT03765112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography angiography
Description: Multiple scans of the retina will be recorded to evaluate microvascular changes.
Study: NCT01886781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v
Description: two capsules of 5 X 10 \^9 c.f.u each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: Micro-crystalline cellulose powder, identical taste, texture and appearance

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Run in period
Description: Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
Study: NCT01287845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1075553
Description: Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
Study: NCT03065439

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static balance testing
Description: Postural sway will be measured using a force plate (Metitur Good Balance System®).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Static balance testing
Description: Postural sway will be measured using a force plate (Metitur Good Balance System®).
Study: NCT00951678

Intervention type: OTHER
Intervention: Observational ultrasonography of venous anatomy
Description: The patient will have ultrasound images obtained of the right and left internal jugular veins as a function of the degree of head rotation and of the right and left femoral veins. Our study is an observational study
Study: NCT03111797

Intervention type: DRUG
Intervention: Morphine
Description: we observe the self-patient controlled morphine consumption during the first 48h after surgery

Intervention type: DRUG
Intervention: Morphine
Description: we observe the self-patient controlled morphine consumption during the first 48h after surgery

Intervention type: OTHER
Intervention: Cardiac output measure
Description: we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )

Intervention type: OTHER
Intervention: Cardiac output measure
Description: we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )
Study: NCT00338988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1500 mg/m\^2 PO twice daily x 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 IV over 2 hours on day 1 of cycle.
Study: NCT01886781

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Run in period
Description: Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wash - out period
Description: Wash - out period following treatment phase of eight weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wash - out period
Description: Wash - out period following treatment phase of eight weeks
Study: NCT00664794

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without acromioplasty
Description: This group will not have their acromion shaved - instead they will receive a repair of their rotator cuff with the scope using sutures or suture anchors.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: with acromioplasty
Description: This group will have Their rotator cuff repaired with sutures or suture anchors and additionally will have the tip of their acromion bone shaved slightly.
Study: NCT00970424

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, oral tablet administered once daily on background of pioglitazone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutogliptin
Description: dutogliptin, oral tablet administered once daily on background of pioglitazone
Study: NCT01484860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUY922
Description: AUY922 is a solution for intravenous administration Dose: 70 mg/m2 over 1 hour, weekly
Study: NCT00528632

Intervention type: OTHER
Intervention: Specimen biopsy and serum laboratory tests
Description: Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy~Laboratory tests measuring levels of plasma total cholesterol and triglycerides

Intervention type: OTHER
Intervention: Specimen biopsy and serum laboratory tests
Description: Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy~Laboratory tests measuring levels of plasma total cholesterol and triglycerides
Study: NCT01864213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ametop cream
Study: NCT02358772

Intervention type: OTHER
Intervention: thrombolysis in a pre-hospital setting (STEMO concept)
Study: NCT01074151

Intervention type: DRUG
Intervention: duloxetine
Description: any exposure to duloxetine that occurred during pregnancy
Study: NCT01395173

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Position change
Description: Patients will be randomly assigned to two groups: Control group (those who will receive standard colonoscopy without position changes) and Position change group (those who will undergo position changes during colonoscope withdrawal during colonoscopy). Subjects in position change group will be asked to shift into three different positions during colonoscope withdrawal.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard
Description: Subjects will undergo standard colonoscopy without position changes during scope withdrawal.
Study: NCT00780624

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIPPV
Description: Ventilator is Bird VIP.
Study: NCT01431950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate
Description: Inhaled corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate
Description: Inhaled corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: Provided as rescue relief of asthma symptoms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol/salbutamol
Description: Provided as rescue relief of asthma symptoms
Study: NCT03819842

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pseudophakic Measurement
Description: standard aphakic measurements will be taken and then pseudophakic measurements will be taken after toric iol implantation. The data produced will aid the surgeon in proper placement of toric iol orientation
Study: NCT03462368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by scaling and root planing only.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antimicrobial photodynamic therapy
Description: In the procedure of subepithelial connective tissue graft, exposed dental roots will be treated by antimicrobial photodynamic therapy with toluidine blue O (10mg/ml)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: After the procedure of subepithelial connective tissue graft the whole surgical site will receive red laser application.
Study: NCT01888809

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive preventive services
Description: Combined evidence-based services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening and referral
Study: NCT03766373

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Drug: OP0201 20mg
Description: OP0201

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Placebo 0mg
Description: Placebo
Study: NCT02633397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat
Description: Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
Study: NCT02275299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
Study: NCT04938739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The first 6 sessions: the cognitive part was explained with the support of a PowerPoint presentation using diagrams, images, and texts. The therapist explained the lumbar engine behavior, the neurophysiologic basis of pain, the importance of the participant's involvement in the treatment (e.g., coping and motivation), and the maintenance of good ergonomics which was aimed at modifying the physiologic response to the pain system.~The second 12 sessions: concepts viewed in the first session were revised; as well, the operant and respondent parts were explained.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home program exercises
Description: Each session will include 10 minutes of aerobic activity (walking or stationary bicycle), followed by five types of muscle stretches and eight types of ground exercises aimed at strengthening the lumbar muscles responsible for stabilization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home program exercises
Description: Each session will include 10 minutes of aerobic activity (walking or stationary bicycle), followed by five types of muscle stretches and eight types of ground exercises aimed at strengthening the lumbar muscles responsible for stabilization.
Study: NCT04251546

Intervention type: DIAGNOSTIC_TEST
Intervention: p2PSA
Description: p2PSA test(for calculation of PHI)

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasonic parameters
Description: Ultrasonic parameters(TPV)

Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal prostate biopsy
Description: Transperineal prostate biopsy for confirmation of prostate cancer or benign disease
Study: NCT02279992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vardenafil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT03591432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transnasal humidified rapid insufflation ventilatory exchange (THRIVE)
Description: Transnasal humidified rapid insufflation ventilatory exchange (THRIVE) is a new technique that is available for use in critically ill patients and in patients with difficult airways. The technique combines the benefits of apneic oxygenation and CPAP with a reduction in CO2 levels through gaseous mixing and flushing of the dead space. THRIVE is administered through a standard, commercially available, nasal, high-flow oxygen delivery system. Insufflation of O2 up to 70 L/min via a purpose-made nasal cannula is used initially to provide preoxygenation, which can be continued during intravenous induction until a definitive airway is secured. The THRIVE technique has been demonstrated to appreciably prolong the safe duration of apnea while avoiding increase in CO2.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Facemask ventilation
Description: Nowadays pre-oxygenation is usually achieved using oxygen delivered via a facemask before induction of anaesthesia; this potentially extends the time available for securing the airway before hypoxaemia to 6 min. In patients undergoing elective surgery, the lungs are normally ventilated with a bag/facemask technique after induction, and this can be repeated if attempts at intubating the trachea are prolonged.
Study: NCT00110955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Q3W 300 mcg darbepoetin alfa

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Q3W dosing of placebo
Study: NCT04115956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan-Flufenamide (Melflufen)
Description: Treatment consist of i.v. melflufen on Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg (20 mg at investigator's discretion) administered on Days 1 and 2 of each 28-day cycle.
Study: NCT02923817

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection
Study: NCT02660112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (+)-Epicatechin
Description: 25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
Study: NCT02748902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ingenol mebutate 0.05% gel
Description: Ingenol mebutate 0.05% gel applied to a minimum of two and a maximum of five common warts on days 1 and 2.
Study: NCT04382768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Hypertonic ibuprofen
Description: Standard of care plus lipid ibuprofen 50mg tid
Study: NCT00787813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-Acetyl Cysteine
Description: oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03626025

Intervention type: OTHER
Group type: OTHER
Intervention: Spaced learning
Description: Instead of learning over a single session, teaching is carried out over a few weekly sessions but maintaining the overall total number of hours spent on teaching
Study: NCT01660919

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Study: NCT04588519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spark Biomedical Roo Transcutaneous Auricular Neurostimulation (tAN) System
Description: Spark Roo tAN System programmed to a pulse width of 250ms; channel 1: 5 Hz, mean intensity 0.3±0.2 mA; channel 2: 100 Hz, mean intensity 0.6±0.2 mA.
Study: NCT03084198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hiHep Bioartificial Liver Support System
Description: Continuous treatment with the hiHep bioartificial liver support system for a minimum of 3 days to a maximum of 14 days. The subject's ultrafiltrated blood is circulated through 4 cartridges. The parameter is set to Circuit 1：120-200ml/min；Circuit 2：30-50ml/min；Circuit 3：200 ml/min.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard care for ALF
Description: A standard of care for subjects with acute liver failure.
Study: NCT01974453

Intervention type: RADIATION
Intervention: Radiation dose
Description: Radiation dose adsorbed by operators

Intervention type: RADIATION
Intervention: Radiation dose
Description: Radiation dose adsorbed by operators

Intervention type: RADIATION
Intervention: Radiation dose
Description: Radiation dose adsorbed by operators
Study: NCT02825277

Intervention type: DEVICE
Group type: OTHER
Intervention: Doppler
Description: acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta

Intervention type: DEVICE
Group type: OTHER
Intervention: Doppler
Description: acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta
Study: NCT00944996

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRI; SNRI; TCA
Description: Tablets or Pills, 1 or 2 per day, more than 2 month